Here’s a strange thing, a seedy curio rather than a massive scandal, but I’d be interested to know what you make of it. This week lots of academics all received the same unsolicited marketing email from a large well known research company called Cyagen, who make transgenic mice, stem cells, and so on. The email was headed “Rewards for your publications”. In it, Cyagen make a rather strange offer: “We are giving away $100 or more in rewards for citing us in your publication!”.

The business model is very specific: if you cite them in an academic paper then you get $100, multiplied by the Impact Factor of the journal (a widely used measure of the journal’s influence). So if you cite them in the New England Journal of Medicine, which has an impact factor of 56, then you will receive $5600 from Cyagen. If you cite them in the British Medical Journal, you get $1700. And so on. Read the rest of this entry »

Me and a dozen other academics all just wrote basically the same thing about Open Science in the Journal Of Clinical Epidemiology. After the technical bits, me and Tracey get our tank out. That’s for a reason: publishing academic papers about structural problems in science is a necessary condition for change, but it’s not sufficient. We don’t need any more cohort studies on the global public health problem of publication bias; we need action, of which the AllTrials.net campaign is just one example (and as part of that, we do still need many more audits giving performance figures on individual companies, researchers and institutions, as I explain here). We have a paper coming shortly on the methods and strategies of the AllTrials campaign that I hope will shed a little more light on this, because policy change for public health is a professional activity, not a hobby. Where academics are sneery about implementation, problems go unsolved, and patients are harmed.

Ironically all these papers on Open Science are behind an academic paywall. The full final text of our paper is posted below. If you’re an academic and you’ve ever wondered whether you’re allowed to do this, but felt overwhelmed by complex terms and conditions, you can check every academic journal’s blanket policy very easily here.

And lastly, if you’re in a hurry: the last two paragraphs are the money shot. Enjoy.

Fixing flaws in science must be professionalised. Read the rest of this entry »

There are some big problems in medicine, and the public are right to be concerned about our shortcomings. Last week we found out that the Chief Medical Officer has written to the Academy of Medical Sciences, asking for an authoritative review into problems in the evidence we use to choose treatments, focusing especially on concerns around statins and tamiflu.

Will the Academy’s review be a whitewash? We hope not. But we are concerned that they may suffer from a lack of vision, and ambition, in trying to fix the problems in medicine.

So here is our call to arms, in a BMJ editorial. Like everything, I hope it is accessible to a general audience as well as doctors and researchers, because we need everyone’s help to fix these problems. We demonstrably cannot move forward on our own, because we have not.

And now, in whispering tones: this list of fixes is taken from a longer list in the last chapter of my super secret new book on statins, out in six months, which I am “not yet talking about” in public (you heard it here first). In that book I set out the evidence on statins, what we know, what we don’t know, and how we can get better data. Then, I set out a Better Medicine Manifesto: clear, deliverable fixes, that will make medicine better, to a soft metal soundtrack.

This link will get you free access to the BMJ piece:

bmj.com/cgi/content/full/bmj.h3397?ijkey=2mYjSgnGBlAGkOP&keytype=ref

As you’ll hopefully know by now from reading Bad Science, Bad Pharma, and my endless columns on the subject, medicine has a problem: the results of clinical trials are routinely and legally withheld from doctors, researchers, and patients. We started the AllTrials.net campaign two years ago to build a global campaign on this issue, and we’ll be publishing a big roundup of what we’ve done soon, along with (crucially, I think) our tactics and methods, in a spirit of pooling knowledge on how to achieve policy change for problems in science. Please do get your professional body to sign up.

This week there was an amazing landmark announcement from the World Health Organisation: they have come out and said that everyone must share the results of their clinical trials, within 12 months of completion, including old trials (since those are the trials conducted on currently used treatments). This is great news, but it’s not enough. The WHO announcement was in PLoS Medicine, with a commentary from WHO staff explaining their reasoning (it’s very good) and a commentary from me, explaining why we need to audit missing data, and act on that audit data.

This, I think, is the only way forward. We have seen that the FDA are unwilling to implement the laws they have available to them, and that other countries such as the UK are unwilling even to consider such legislation. In the absence of serious engagement on this issue from the policy community, now doctors, payers (such as the NHS), and enlightened funders need to take action themselves. If we fail to do so, we may be judged harshly by our patients. Read the rest of this entry »

There is an excellent research paper published today in the BMJ, showing that academic press releases routinely exaggerate scientific findings and mislead the public.

This is something I’ve often covered. In this story, for example, the BMJ’s own press release about their own paper was hopelessly and entirely misleading. And after this story, featuring a misleading press release from Great Ormond Street Hospital, the head of that institution wrote a paranoid and misguided defense (which I have proudly reprinted, in my new book, in full). Read the rest of this entry »

YouGov have produced a fun, popular new parlour game. You give the site the name of a celebrity, author, TV show, pet, activity, or anything; and it gives you a lot more information in return. Essentially: “other things that such a person typically does and likes”. So, the “favourite dishes” of people who read Ben Goldacre books are Vegetarian Thali, Gravlax (whatever that is), and Pork Gyoza. Fans of comedian Richard Herring report that their favourite TV show is Stewart Lee (insensitive, given the *bitter* rivalry). Newsnight profiled their viewers at the end of their show on Tuesday (self-absorbed and listen to New Order). It’s fun to play around with.

But these statistics have been misinterpreted, because they have been mis-presented by YouGov.
Read the rest of this entry »